GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro

  • Signal Transduct Target Ther. 2020 Nov 17;5(1):267. doi: 10.1038/s41392-020-00391-5.
Kyung Soo Hong  1 ,  June Hong Ahn  1 ,  Jong Geol Jang  1 ,  Jong Ho Lee  2 ,  Hong Nam Kim  3  4 ,  Dongha Kim  5 ,  Wonhwa Lee  6
Affiliations
  • 1. Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, 42415, Republic of Korea.
  • 2. Department of Laboratory Medicine, College of Medicine, Yeungnam University, Yeungnam University Medical Center, Daegu, 42415, Republic of Korea.
  • 3. Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea. [email protected].
  • 4. Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology (UST), Seoul, 02792, Republic of Korea. [email protected].
  • 5. Department of Anatomy, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea. [email protected].
  • 6. Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. [email protected].
PMID: 33203839 DOI: 10.1038/s41392-020-00391-5
Products